

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 September 2012 (27.09.2012)



(10) International Publication Number
WO 2012/129145 A8

(51) International Patent Classification:

A61K 31/4985 (2006.01) *A61K 45/06* (2006.01)
A61K 31/517 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2012/029598

(22) International Filing Date:

19 March 2012 (19.03.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/454,059 18 March 2011 (18.03.2011) US

(71) Applicant (for all designated States except US): **OSI PHARMACEUTICALS, LLC** [US/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **THOMSON, Stuart** [GB/US]; OSI Pharmaceuticals, LLC, 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **BROWN, Eric, N.** [US/US]; OSI Pharmaceuticals, LLC, 2860 Wilderness Place, Boulder, CO 80301 (US). **CHAU, Andrew** [CA/US]; OSI Pharmaceuticals, LLC, 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **FRANKLIN, Maryland** [US/US]; OSI Pharmaceuticals, LLC, 2860 Wilderness Place, Boulder, CO 80301 (US). **IWATA, Kenneth,**

K. [US/US]; OSI Pharmaceuticals, LLC, 1 Bioscience Park Drive, Farmingdale, NY 11735 (US).


(74) Agents: **FORMAN, Frank, W.** et al.; OSI Pharmaceuticals, LLC, 1 Bioscience Park Drive, Farmingdale, NY 11735 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: NSCLC COMBINATION THERAPY



(57) Abstract: A method of treating NSCLC comprising in some aspects administering OSI-906 and an EGFR inhibitor to a patient having NSCLC having an activating EGFR mutation, as disclosed herein.



Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:

11 April 2013

(15) Information about Correction:

see Notice of 11 April 2013